Latest News

Transcend Therapeutics Announces Completion of Acquisition by Otsuka Pharmaceutical

Transcend Therapeutics Receives FDA National Priority Voucher for TSND-201 in PTSD

Otsuka Pharmaceutical to Acquire Transcend Therapeutics

IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD

New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology

Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND- 201 (methylone) for the Treatment of PTSD

Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD

TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2

TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of
TSND-201 in PTSD

Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201